Healthtech seed investors look for a defensible, clinically credible product, a team that can execute, and evidence the addressable market is large enough to justify a venture-scale return. At seed stage, that translates into specific pitch-deck requirements: clinical validation, a clear regulatory pathway, documented patient-outcome data, and a plain answer to who actually pays for the product. Investors also read a 2025 deck against a funding market that has shifted hard toward one category.
AI-enabled startups captured 62% of all U.S. digital health venture dollars in the first half of 2025, the first time AI-enabled companies took a majority of the sector's funding, according to Rock Health's H1 2025 report. A founder pitching today is competing for capital against that backdrop, whether or not the product itself uses AI.
Table of Contents
- What Investors Expect to See on the Clinical and Regulatory Slides
- Why the Market Is Rewarding AI-Enabled Pitches Specifically
- How Big Is the Funding Pool, and What Gets the Largest Checks
- How to Present Clinical Claims Without Losing the Investor
- What the Evidence Doesn't Cover
What Investors Expect to See on the Clinical and Regulatory Slides
Healthtech seed investors treat clinical validation, a defined regulatory pathway, and documented patient-outcome data as baseline requirements, not differentiators, according to an investor-focused healthtech fundraising guide. A deck that lacks any one of these is read as incomplete, regardless of how strong the market opportunity looks elsewhere. This means a founder needs more than a product demo or a user-satisfaction survey. Investors want to see what outcome the product changes for a patient, how that outcome was measured, and where the product stands in any applicable approval process — for example, progress through FDA review if the product is regulated as a medical device or software.
The same guide lists reimbursement clarity as a required element alongside clinical evidence: naming whether the payer, the employer, the patient, the provider, or a pharmaceutical company foots the bill, according to the Qubit Capital guide. That detail shapes the entire go-to-market and revenue model, so investors expect it spelled out rather than left as a future milestone. A New Zealand government innovation agency's healthtech investment framework describes the same baseline from the investor's side: healthtech investors weigh a defensible product, a strong team, and a sufficiently large addressable market together, while noting that what counts as "defensible" differs across software, medical devices, and drug-based startups, according to Callaghan Innovation's healthtech investment framework. A software-only product may lean on data and clinical validation for its defensibility, while a device startup leans more on regulatory barriers to entry.
Why the Market Is Rewarding AI-Enabled Pitches Specifically
The capital shift toward AI-enabled digital health startups is not marginal — it is now the majority of the money. Rock Health found AI-enabled companies took 62% of U.S. digital health venture funding in H1 2025, and AI-enabled rounds averaged $34.4 million, an 83% premium over the $18.8 million average for non-AI-enabled rounds, according to Rock Health's data reported by Fierce Healthcare. That premium shows up in deal size, not just deal count.
U.S. digital health startups overall raised $6.4 billion in H1 2025, up from $6.0 billion a year earlier, even though the number of deals fell from 273 to 245, pushing the average deal size from $20.4 million to $26.1 million, according to Rock Health's H1 2025 report. Fewer deals, each one larger, is consistent with investors concentrating capital in startups — disproportionately AI-enabled ones — that clear a higher evidence bar before a check is written. This dynamic tells a founder something practical: an AI feature by itself is not the pitch. The premium investors pay for AI-enabled startups tracks back to the same clinical, regulatory, and outcomes evidence described above — AI claims draw extra scrutiny on exactly those points, since an algorithm's clinical claim needs its own validation story.
How Big Is the Funding Pool, and What Gets the Largest Checks
Globally, digital health funding rose about 19% year-over-year to $22.3 billion in 2025, even as deal count fell 9% to 1,474 — pushing average deal size up 29% to $20.3 million, according to CB Insights' 2025 digital health report. As with the U.S.-only figures, the pattern is fewer, bigger deals.
The largest checks are going to a narrow slice of companies. Mega-rounds of $100 million or more made up 44% of total digital health funding in 2025 — about $9.8 billion across 48 deals — and every one of the 14 new digital health unicorns that year was an AI company, according to CB Insights' data reported by HIT Consultant. For a seed-stage founder, this context matters less as a target to hit and more as a signal of where investor attention and larger follow-on rounds are flowing — a seed round today is increasingly a first step toward a market where AI-enabled companies dominate the biggest outcomes.
How to Present Clinical Claims Without Losing the Investor
A review of healthtech pre-seed decks that successfully raised funding found that investors penalize unexplained clinical and technical jargon, rewarding founders who make medical claims understandable without requiring outside research into terminology, according to a review of healthtech pre-seed pitch decks. A clinical claim that only a specialist can parse works against the founder, even when the underlying science is sound. Practical steps that follow from the research:.
- Define every clinical or regulatory term the first time it appears, rather than assuming investor familiarity.
- Pair each outcome claim with the specific data behind it — a study, a pilot result, or a named metric — rather than a general statement of effectiveness.
- State the regulatory pathway and its current stage plainly, even if the stage is early.
- Name the payer in one sentence: who pays, and under what arrangement.
- If the product uses AI, explain what the AI does and what evidence supports its specific clinical claim, rather than listing "AI-powered" as a feature.
What the Evidence Doesn't Cover
No primary venture capital fund has published its own seed-stage-specific healthtech pitch-deck checklist. The clinical-evidence, regulatory, and reimbursement criteria described above come from fundraising-advisory guides and an innovation-agency framework, not from an investor's own published diligence standard. A founder should treat these as well-documented common practice across the advisory and funding-data sources available, rather than a rule issued by any single fund — individual investors may weight clinical evidence, team strength, and market size differently depending on the product category and their own portfolio focus.